In the study, which was published in The BMJ, researchers analyzed data from 195 countries and territories using the 2021 ...

Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-yearStrong growth in key commercial metrics, including ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

A new study published in Cell Reports reveals a breakthrough discovery linking genetic variants in the gene ITSN1 to a ...

A new study published in Cell Reports reveals a breakthrough discovery linking genetic variants in the gene ITSN1 to a ...

Scientists have identified a rare genetic mutation in ITSN1 that increases the risk of Parkinson’s disease by up to tenfold, ...

Parkinson's disease affects 8.5 million people globally, with symptoms including tremors, slow movement, and muscle stiffness ...

A new study has identified genetic variants in the ITSN1 gene that significantly increase the risk of developing Parkinson’s disease.

Inc. , today announced a definitive merger agreement under which Bristol Myers Squibb ("BMS") will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash ...